More Articles

WHO proposal offers clarity for biosimilar nomenclature Biosimilars/General | Posted 14/08/2014

Following requests from drug regulatory authorities worldwide, the World Health Organization (WHO) has released a draft Biological Qualifier (BQ) proposal on which to base a globally recognized&nbs...

Biosimilar events from 2012 to 2014 Reports | Posted 14/08/2014

The last few years have seen biosimilars the hot topic on the agenda of most countries. This is evidenced by the increasing number of biosimilars manufacturers as well as approvals for biosimilars...

Right of appeal provision in CETA Generics/Research | Posted 14/08/2014

The Comprehensive Economic and Trade Agreement (CETA) between the European Union (EU) and Canada has the potential to have a negative affect on the generics industry in Canada [1], with certain pro...

Biosimilars in the treatment of chemotherapy-induced anaemia Biosimilars/Research | Posted 14/08/2014

A study of the use of epoetin biosimilars in the therapeutic management of anaemia secondary to chemotherapy in haematology and oncology has shown the biosimilars to be effective and well tolerated...

Biosimilars of cetuximab Biosimilars/General | Posted 14/08/2014

Last Update: 1 April 2016 Cetuximab is a chimeric (mouse/human) monoclonal antibody. It inhibits epidermal growth factor receptor (EGFR) and is used to treat metastatic colorectal cancer, meta...

Generics deals for Mylan, Pfizer and Sun Pharma Pharma News | Posted 14/08/2014

Not to be beaten by biosimilars manufacturers, generics makers are also jumping on the ‘deals’ bandwagon, with a plethora of collaborations announced in the past weeks.

Coherus starts phase III biosimilar etanercept trial Biosimilars/News | Posted 14/08/2014

US-based biosimilars developer Coherus BioSciences (Coherus) announced on 23 June 2014 the start of a global phase III trial for a biosimilar version of etanercept.

Biosimilars deals coming thick and fast Biosimilars/News | Posted 14/08/2014

Biosimilar collaborations are still the latest fashion, with new deals being made between Cipla and Mabpharm, Strides Arcolab and Oncobiologics, and NeuClone and the Serum Institute.